COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:

Key Record Dates Identifier: NCT01877005
Brief Title: A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (HIJAK)

First Submitted : June 11, 2013
First Submitted that Met QC Criteria : June 11, 2013
First Posted : June 13, 2013 (Estimate)

Last Update Submitted that Met QC Criteria : August 21, 2018
Last Update Posted : August 22, 2018